Immune-mediated mechanisms of resistance to molecular targeting therapy against NSCLC
Project/Area Number |
26290050
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Tumor therapeutics
|
Research Institution | Keio University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
菰原 義弘 熊本大学, その他の研究科, 准教授 (40449921)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥16,250,000 (Direct Cost: ¥12,500,000、Indirect Cost: ¥3,750,000)
Fiscal Year 2016: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2015: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2014: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
Keywords | 腫瘍免疫 / 肺腺癌 / ミエロイド細胞 / PD-1 / EGFR-TKI / 治療抵抗性 / 非小細胞癌 / EGFR変異 / マクロファージ / 癌 / 免疫 / 免疫チェックポイント分子 / 非小細胞肺癌 / 肺非小細胞癌 |
Outline of Final Research Achievements |
As immune-mediated factors which are critical to reduce sensitibity and/or trigger resistance to EGF-TKI agains NSCLC through the analysis of novel spontaneous NSCLC models and clinical samples, we identified signaling pathways related to differentiation and activation of M2 macrophages and MDSC, two major immunosuppressive myeloid cells, as important factor to predict low sensitivity and emergence of resistant-associated mutation (T790M) to EGF-TKI against lung adenocarcinoma. Moreover, the combination of CSF1 inhibitors and EGF^TKI dramatically reduced incidence of spontaneous lung adenocarcinoma in mouse models. On the other hands, there are no involvement of immune checkpoint pathways as immune factors to regulate lung adenocarcinoma.It is important to clarify novel immune-mediated mechanisms other than immune checkpoint such as PD-1 to regulate responsiveness of EGFR-TKI against lung adenocarcinomas.
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Interleukin-17A Promotes Lung Tumor Progression Through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade2017
Author(s)
Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE2, Silkes M, Jones R, Jinushi M, Kulkarni M, Carretero J, etal.
-
Journal Title
Journal of Thoracic Oncology
Volume: 印刷中
Related Report
Peer Reviewed / Int'l Joint Research
-
[Journal Article] Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.2017
Author(s)
Goto K, Annan DA, Morita T, Li W, Muroyama R, Matsubara Y, Ito S, Nakagawa R, Tanoue Y, Jinushi M, Kato N.
-
Journal Title
Scientific Reports
Volume: 6
Issue: 1
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
[Journal Article] The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas2015
Author(s)
Yoshihiro Komohara, Tomoko Morita, Dorcas A. Annan, Hasita Horlad, Koji Ohnishi, Sohsuke Yamada, Toshiyuki Nakayama, Shohei Kitada, Shinya Suzu, Ichiro Kinoshita, Hirotoshi Dosaka-Akita, Koichi Akashi, Motohiro Takeya, Masahisa Jinushi
-
Journal Title
Cancer immunology research
Volume: 3
Issue: 9
Pages: 999-1007
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-